Abstract:In Positron Emission Tomography (PET) quantification of physiological parameters at the voxel level may result in unreliable estimates due to the high noise of voxel time activity curves. Global-Two-Stage (GTS), an estimation technique belonging to the group of “population approaches”, can be used to tackle this problem. GTS was previously tested on simulated PET data and yielded substantial improvements when compared to standard estimation approaches such as Weighted NonLinear Least Squares (WNLLS) and Basis Function Method (BFM). In this work GTS performance is assessed in a clinical context using the neuroinflammation marker [11C]-(R)-PK11195 applied to a cohort of Huntington's disease (HD) patients with and without symptoms.Parametric maps of binding potential (BPND) of 12 normal controls (NC), 9 symptomatic and 9 presymptomatic HD patients were generated by applying a modified reference tissue model that accounts for tracer vascular activity in both reference and target tissues (SRTMV). GTS was then applied to SRTMV maps and its performance compared with that of SRTMV. Three smoothed versions of SRTMV, obtained by filtering the original SRTMV maps with Gaussian filters of 3 mm, 5 mm and 7 mm Full Width Half Maximum (FWHM), were also included in the comparison. Since striatal degeneration is the hallmark of HD, sensitivity was assessed for all methods by computing the mean of z-scores in caudate, putamen and globus pallidus in the voxel-by-voxel statistical comparison of BPND between HD and NC.Application of GTS to parametric maps brought a substantial qualitative improvement to SRTMV maps to the extent that anatomical structures often became visible. In addition, most parameter estimates that were outside the physiological range with SRTMV were corrected by GTS. GTS yielded a 2.3-fold increase in sensitivity with respect to SRTMV for the symptomatic cohort (mean of striatal z-scores of 0.76 for SRTMV and 1.79 for GTS) and an even more substantial increase for the presymptomatic cohort (mean of striatal z-scores of 0.34 for SRTMV and 0.96 for GTS). The sensitivity of GTS was similar to the one obtained with a filter of 7 mm FWHM applied to the initial SRTMV maps but GTS images were not characterized by the notable loss of resolution typical of smoothed maps. GTS, additionally, does not require to change/define settings according to the tracer and level of noise, whereas the choice of the FWHM value of the Gaussian filter normally employed in the smoothing procedure is typically arbitrary.GTS is a powerful and robust tool for improving the quality of parametric maps in PET. The method is particularly appealing in that it can be applied to any tracer and estimation method, provided that initial estimates of the parameter vector and of its covariance are available. Although the benefits of GTS are far from being exhaustively assessed, the significant improvements obtained both on real and simulated data suggest that it could become an important tool for dynamic PET in the future.

Microglia Activation in Basal Ganglia Is a Late Event in Huntington Disease Pathophysiology

Microglial Activation Induced by Neurodegeneration

Microglial proliferation and astrocytic protein alterations in the human Huntington's disease cortex

Brain microglia activation and peripheral adaptive immunity in Parkinson's disease: a multimodal PET study

Activated Microglia in the Early Stage of a Rat Model of Parkinson's Disease: Revealed by PET-MRI Imaging by [18F]DPA-714 Targeting TSPO

Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia

Gray Matter Microglial Activation in Relapsing Vs Progressive MS: A [F-18]PBR06-PET Study.

Microglia measured by TSPO PET are associated with Alzheimer's disease pathology and mediate key steps in a disease progression model

Human Huntington’s disease pluripotent stem cell-derived microglia develop normally but are abnormally hyper-reactive and release elevated levels of reactive oxygen species

P.3.f.007 Microglia is Widespread Activated in Recent Onset Schizophrenia: Evidence from PET and Post Mortem Studies

Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases

Microglial Activation and Progression of Nigrostriatal Dysfunction in Isolated REM Sleep Behavior Disorder

Imaging Striatal Microglial Activation in Patients with Parkinson’s Disease

Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis

Linking White Matter and Deep Gray Matter Alterations in Premanifest Huntington Disease.

Microglia Activation in Recent Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Study

Longitudinal imaging highlights preferential basal ganglia circuit atrophy in Huntington's disease

Post-Mortem validation of in vivo 18kDa Translocator Protein (TSPO) PET as a microglial biomarker

Neuroinflammatory component of gray matter pathology in multiple sclerosis

Early prognosticators of later TSPO-PET-measurable microglial activation in multiple sclerosis

[18F]-DPA-714 PET as a specific in vivo marker of early microglial activation in a rat model of progressive dopaminergic degeneration